Monday, May 7, 2012

Novartis builds further evidence on Lucentis superior profile over Avastin

Novartis has announced interim results from the IVAN study (Inhibit VEGF in Age Related choroidal macular Neovascularization) which showed that Avastin failed to match Lucentis in vision gains at year one. This data in conjunction with two year safety data from CATT study  should put pressure on ophthalmologists using Avastin as an off-label treatment in AMD.
 The new IVAN data also supports that Lucentis when administered as needed is as effective as monthly therapy.

2 comments:

  1. "Novartis has announced interim results from the IVAN study which showed that Avastin failed to match Lucentis in vision gains at year one". REALLY??? That doesn't seem to be the way that the News Channels are reporting it. I haven't seen the IVAN Study reports but this isn't stacking up!!!

    ReplyDelete
  2. I agree, the analysis is being represented differently by the company and the news channel. According to the news channel, the two drugs were comparable, while Novartis says Avastin did not show non-inferiority. I am yet to see the detailed data as well.

    ReplyDelete